Nasolacrimal Duct Obstruction Following Radioactive Iodine: An Update on Counseling Recommendations for Thyroid Cancer Survivors
Authors' conclusion
Higher initial and cumulative treatment dose of RAI, and multiple treatment sessions, increased likelihood of subsequent development of nasolacrimal duct obstruction. We recommend increased counseling and screening of thyroid cancer survivors undergoing RAI for thyroid carcinoma at lower doses than previously indicated, particularly in those who undergo multiple treatment sessions.
Study context
- Population
- Patients treated with radioactive iodine (RAI) for thyroid carcinoma
- Participants
- 50 patients
- Comparison
- RAI-treated patients with symptomatic nasolacrimal duct obstruction vs matched RAI-treated controls without
- Group 1n = 25
- Group 2n = 25reference
- Outcome
- Risk factors for nasolacrimal duct obstruction
Methodological detailsage- and gender-matched controls
- Age- and gender-matched controls
Main finding
As reported in the abstract
Cumulative RAI dose
Group 1
223.4
mean · mCi (8.27 Gbq)
Group 2
121.4
mean · mCi (4.49 Gbq)
P = 0.0092
Observational data: associations, not effects.
Further findings
| Outcome | Group 1 | Group 2 | P value |
|---|---|---|---|
| Initial RAI treatment dose | mean 128.9 mCi (4.77 Gbq) | mean 100.0 mCi (3.70 Gbq) | P = 0.0317 |
| Number of RAI treatment sessionsMean | 1.48 (range 1–3) | 1.16 (range 1–2) | P = 0.0387 |
Original publication
Nasolacrimal Duct Obstruction Following Radioactive Iodine: An Update on Counseling Recommendations for Thyroid Cancer Survivors. Endocr Pract. Published 9 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →